Biocon shares gain over 2% on launch of cancer drug KRABEVA in India

Biocon share price gained 2.5 percent intraday Thursday after the biopharmaceuticals firm has launched KRABEVA, a biosimilar Bevacizumab, in India.

The drug is used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.

“We believe KRABEVA will be an important addition to oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India,” Arun Chandavarkar, CEO and joint MD, Biocon said.

KRABEVA is the second key oncologic biosimilar product from Biocon’s global biosimilars portfolio to be launched in India, in order to address the unmet patient need for affordable biological therapies.

The product is being offered to patients at an MRP of Rs 24,000 for 100 mg / 4 ml vials and Rs 39,990 for 400 mg / 16 ml vials.

KRABEVA is being launched post successful completion of phase III clinical trials and approval of company’s marketing authorisation application by the Drug Controller General of India.

At 11:02 hours IST, the stock price was quoting at Rs 418.50, up Rs 9.90, or 2.42 percent on the BSE.

source:-.moneycontrol.

Biocon climbs 2.65% on launch of cancer medicine

Shares of Biocon jumped as much as 2.65 per cent in Tuesday as the company has launched its cancer biosimilar drug KRABEVA in India.

Following a positive open at Rs 410 against the previous close of Rs 408.60, the scrip touched an intraday high of Rs 419.75 and a low of Rs 405.80. In terms of equity volume, 10.29 lakh shares traded on the BSE.

The stock ended the session up by 1.09 per cent at Rs 413.05.

According to a BSE filing, the biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India.

Biocon CEO and Joint MD Arun Chandavarkar said: “With KRABEVA, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer.”

The company believes that the product will be an important addition to its oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India, he added.

Source:-thehindubusinessline

Samsung Exynos 9 Series 9810 SoC Launched, Based on 10nm FinFET Process

Samsung Exynos 9 Series 9810 SoC Launched, Based on 10nm FinFET Process

HIGHLIGHTS

  • Samsung unveils the Exynos 9 Series 9810 SoC
  • It is likely to debut on the company’s Galaxy S9
  • The chipset can be expected to feature on phones next year

Samsung has announced a new flagship mobile processor in the Exynos 9 series, built on the 10nm process. As is traditional with such unveils, it can be expected that the new new Exynos 9 Series 9810 SoC will be the processor powering the company’s next flagship smartphone, the Galaxy S9.

The Samsung Exynos 9810 packs the company’s third-generation custom CPU cores and also comes with an upgraded GPU. Samsung is also touting support for Gigabit LTE modem which can offer what Samsung calls industry’s first 6CA (carrier aggregation) support. Samsung says that the new Exynos 9 Series 9810 SoC has been built on second-generation 10nm process technology.

The Exynos 9 Series is said to be the company’s first processor chipset built on the 10-nanometre FinFET process technology.

The South Korean company earlier this year unveiled its premium application processor, the Exynos 9 Series 8895. Some of the highlights of the Exynos 9 Series 8895 processor were embedding of a Gigabit LTE modem that can support five carrier aggregation, or 5CA. It supports LTE Cat. 16 with download speeds of up to 1Gbps and upload speeds of up to 150Mbps (Cat. 13). The chipset was used in the Samsung Galaxy S8 and Galaxy S8+ as well as the company’s Galaxy Note 8 phablet.

Rumours have pointed to early next year launch of the Qualcomm Snapdragon 845 SoC which could be seen as the competitor to the Exynos 9 Series 9810 SoC. The Snapdragon 845 SoC is said to be built on a new faster, more efficient 7nm fabrication process. Furthermore, the new Qualcomm SoC is also said to debut on the Galaxy S9 next year.

For Samsung’s upcoming flagships, the company is widely expected to retain Infinity Displays which allow the 5.8-inch and 6.2-inch screens to come with a relatively compact factor. The upcoming Galaxy S9 and Galaxy S9+ smartphones are rumoured to use the same screen sizes as well as the same curved design first seen on the Galaxy S8 and Galaxy S8+.

[“Source-gadgets.ndtv”]

Tencent Sees Profit on Smartphone Games, WeChat Now Has 980 Million Users

Tencent Sees Profit on Smartphone Games, WeChat Now Has 980 Million Users

Chinese Internet giant Tencent Holdings Ltd on Wednesday posted a 69 percent jump in quarterly net profit, beating expectations, on strong smartphone games revenue.

Net profit for the three months ended September rose to CNY 18 billion ($2.72 billion), China’s largest social media and gaming company said in a filing to the Hong Kong Stock Exchange.

This was above an average estimate of CNY 15.18 billion from six analysts polled by Thomson Reuters.

Revenue rose 61 percent to 65 billion yuan, against an estimate of CNY 60.78 billion.

Monthly active users of the social media mobile app WeChat hit 980 million, up from 963 million three months ago.

Revenue from smartphone games, helped by its popular title Honour of Kings, grew by 84 percent to CNY 18.2 billion in the quarter, Tencent said in the filing.

[“Source-gadgets.ndtv”]